Nerandomilast, a PDE4 inhibitor, has shown significant efficacy in progressive pulmonary fibrosis (PPF), offering an ...

FDA has granted orphan drug designation to FS2 (kynurenic acid) for the investigational treatment of idiopathic pulmonary ...

CNW/ - BirchBioMed Inc., a leading clinical stage biopharmaceutical company, expert in the development of products for ...

Nerandomilast, a PDE4B inhibitor, is a new treatment option for IPF, showing better tolerability than nintedanib and ...

The most common chronic progressive fibrosing ILD is IPF.1,2 PPF is another form of progressive fibrotic lung disease that ...

Researchers at Tulane University have identified a potential new way to treat idiopathic pulmonary fibrosis (IPF), a deadly and currently incurable lung disease that affects more than 3 million people ...

A metro woman was given a few years to live in 2022, after being diagnosed with a serious lung disease. However, thanks to a ...

The effect of pollution exposure on IPF severity and progression was not modified by MUC5B promotor polymorphism or telomere length. Long-term exposure to fine particulate matter is associated with a ...

This condition has been described by Michael J. Stephen in his 2021 book “Breath Taking” as the “most frustrating and disheartening of all the diseases in pulmonary medicine.” Over a frighteningly ...

Christopher Kennedy's unexpected IPF diagnosis after a routine X-ray highlights the insidious nature of this lung disease. Affecting mostly older adults, IPF causes lung scarring, leading to ...

A recent study validates that combining genetic and clinical data can predict the risk for pulmonary fibrosis in patients ...